Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics, Inc., executed a substantial divestment of company equity on June 25, 2026. The transaction involved the sale of 24,100 shares of common stock, generating a total proceeds value of $732,158. This sale was facilitated through a Rule 10b5-1 trading plan established in December 2025, a mechanism designed to allow executives to trade company stock within a predefined framework. The execution price for these shares ranged between $30.00 and $30.88 per share, resulting in a weighted average sale price of $30.38.
This transaction occurred against a backdrop of notable market movement, as Capricor Therapeutics stock was trading at $23.80 at the time of reporting. This price point represents a decline of nearly 20% from the price at which Bergmann sold his shares. Despite this recent downward pressure, the stock has demonstrated substantial appreciation over the preceding twelve-month period, delivering a 140% return.
Prior to the sale, Bergmann exercised stock options to acquire an identical quantity of 24,100 shares on the same day. These shares were acquired at an exercise price of $3.18 per share, totaling $76,638. The stock options, which had an exercise price of $3.18, vested 1/48th on the first day of each month commencing February 1, 2022, and are set to expire on January 3, 2032.
Following these transactions, Mr. Bergmann directly holds 11,223 shares of Capricor Therapeutics common stock. Additionally, he holds 91,980 derivative shares in the form of stock options. According to InvestingPro analysis, analysts predict the company will be profitable this year, with the stock trading near its Fair Value. Investors seeking deeper insights can access CAPR’s comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Capricor Therapeutics reported a larger-than-expected loss for the first quarter of 2026, with an earnings per share (EPS) of -$0.59, missing analysts’ expectations of -$0.52 by 13.46%. Despite the earnings miss, B.Riley maintained a Buy rating on Capricor Therapeutics, keeping the stock price target at $63, citing progress in regulatory and commercial matters. The company has sufficient cash reserves to fund operations into the fourth quarter of 2027.
Capricor is actively engaged with the U.S. Food and Drug Administration, which has scheduled an advisory committee meeting for July 29, 2026, to discuss the Biologics License Application for Deramiocel, its investigational therapy for Duchenne muscular dystrophy. The application is backed by data from several clinical trials, including the Phase 3 HOPE-3 trial, which met its primary and key secondary endpoints. Capricor also presented five-year data from its HOPE-2 Open-Label Extension study at a recent conference. Additionally, the company disclosed a rescission filing against Nippon Shinyaku and NS Pharma.
The transaction highlights the intersection of executive compensation structures and regulatory milestones within the biotechnology sector. Bergmann's sale, executed under a pre-arranged plan, occurs as the company navigates critical regulatory reviews and financial performance metrics. The discrepancy between the exercise price of the options and the subsequent sale price underscores the potential financial benefits of equity-based compensation for executives, even as the company faces near-term earnings challenges. The ongoing engagement with the FDA and the upcoming advisory committee meeting represent significant inflection points for the company's pipeline and market valuation.
Market participants are closely monitoring the company's cash runway and regulatory trajectory. The reported earnings miss, while notable, was met with maintained analyst confidence, suggesting that underlying business fundamentals and pipeline progress remain key drivers of investor sentiment. The company's ability to fund operations through 2027 provides a buffer as it pursues regulatory approvals for its investigational therapies. The rescission filing against Nippon Shinyaku and NS Pharma adds another layer of complexity to the company's strategic landscape, potentially impacting future commercialization efforts and partnerships.
The stock's recent volatility, including the nearly 20% decline from Bergmann's sale price, reflects the inherent risks associated with biotechnology investments. While the stock has delivered significant returns over the past year, the near-term price action indicates market sensitivity to earnings reports and regulatory developments. The upcoming FDA advisory committee meeting on July 29, 2026, will be a critical catalyst for the stock, as the decision on the Biologics License Application for Deramiocel could significantly influence the company's future revenue potential and market position.